Further, Guardant Health’s newly introduced, advanced molecular profiling test requires 40% fewer tissue slides than the industry norm, allowing testing of more patients with less precious tissue.

Mel Gibson criticized California Gov. Gavin Newsom and LA Mayor Karen Bass for their handling of violent protests while on the "Arroyo Grande" podcast.

Precision oncology specialist Guardant Health (NASDAQ: GH) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped ...

Guardant Health exceeds Q1 expectations, boosts growth outlook, and gains from favorable pricing and approvals. Read more about GH stock here.

Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China.

Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform Multi-year ...

Stephens restated their overweight rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a research report released on Wednesday,Benzinga reports. Stephens currently has a $55.00 ...

Guardant accuses Natera of trade secret theft amid ‘jealousy’ over CRC blood test Guardant Health has filed a lawsuit against its competitor, Natera, alleging the misappropriation of trade secrets ...

Guardant Health, Inc. (NASDAQ:GH – Get Free Report)’s stock price traded down 6.9% on Friday following a weaker than expected earnings announcement. The stock traded as low as $43.60 and last ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade secrets related to cancer-detection blood tests.

Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer ...

Revenue was reported as $739 million. Guardant Health expects full-year revenue in the range of $850 million to $860 million.